Prostate cancer is the most commonly diagnosed non-skin cancer in American men, yet most cases grow slowly and never become life-threatening. Understanding how the disease behaves — and how doctors tell a slow-growing tumor from an aggressive one — helps you make calmer, better-informed decisions if an abnormal result ever appears on your chart. In this article you will learn what the disease is, the symptoms to watch for, who is most at risk, and how modern diagnosis now combines the PSA blood test, MRI, and a tissue biopsy. You will also see how doctors grade and stage a tumor, what treatment options exist from active surveillance to surgery, and how to weigh the pros and cons of PSA screening with your physician.
What is prostate cancer?
The prostate is a walnut-sized gland that sits below the bladder and wraps around the upper part of the urethra, the tube that carries urine out of the body. It produces fluid that nourishes and protects sperm. Prostate cancer develops when cells in this gland begin to grow and divide in an uncontrolled way, forming a tumor.
What makes this disease unusual is how differently it can behave. Many prostate tumors are indolent, meaning they grow so slowly that they never cause symptoms or shorten a man’s life. Others are aggressive and can spread beyond the gland to lymph nodes or bone. This is why the central question is not only whether cancer is present, but whether that cancer is likely to cause harm. Telling those two situations apart is the theme that runs through every section below.
The disease is common, and the risk rises steadily with age. The reassuring news is that when a tumor is caught while still confined to the gland, long-term survival is very high.
Symptoms and warning signs of prostate cancer
Early prostate cancer usually causes no symptoms at all. Because the gland surrounds the urethra, noticeable problems tend to appear only once a tumor grows large enough to press on nearby structures, or once the disease has spread. That silence is precisely why testing decisions matter.
Urinary changes
When symptoms do occur, they often involve urination: a weak or interrupted stream, difficulty starting, a frequent need to urinate (especially at night), or a feeling that the bladder has not fully emptied. Importantly, these same symptoms are far more often caused by benign prostatic hyperplasia, a non-cancerous enlargement of the prostate that is extremely common with age. A urinary infection can cause similar complaints; if you want to understand that overlap, read our guide to urinary tract infections.
Blood and advanced signs
Blood in the urine or semen can occur and always deserves medical evaluation. To learn what else can turn urine pink or red, review our article on blood in the urine. Because bleeding can also start in the bladder rather than the prostate, you may also want to read our guide to bladder cancer warning signs. Pain in the lower back, hips, or pelvis that does not go away can be a sign that prostate cancer has spread to bone, although back pain has many ordinary causes. Unexplained weight loss or fatigue are late, nonspecific signs.
What raises the risk of prostate cancer
No one can fully control their risk, but several factors are well established.
- Age: the single biggest factor. Most cases are diagnosed after age 65, and the disease is uncommon before 50.
- Family history: having a father or brother with the disease roughly doubles a man’s risk.
- Inherited gene changes: mutations in the BRCA1 or BRCA2 genes — the same genes linked to breast and ovarian cancer — raise the risk of aggressive disease, as do Lynch syndrome mutations.
- Race and ancestry: men of African descent are diagnosed more often, tend to develop the disease younger, and are more likely to have aggressive tumors.
- Other factors: obesity is linked to a higher risk of aggressive disease, while diet and lifestyle appear to play a smaller, less certain role.
Knowing your personal risk profile helps you and your doctor decide whether and when testing makes sense — a conversation covered later in this guide.
How prostate cancer is diagnosed
Modern diagnosis is a step-by-step pathway designed to find dangerous cancers while avoiding unnecessary alarm over harmless ones. It usually begins with a blood test and, increasingly, an MRI scan before any biopsy is considered.
The PSA blood test
Prostate-specific antigen, or PSA, is a protein made by the prostate that circulates in the blood. Higher levels can signal cancer, but also benign enlargement, infection, recent ejaculation, or even a long bike ride. There is no single normal number, though many laboratories flag levels above 4 nanograms per milliliter for further discussion. For a fuller explanation of what the figures mean, read our complete guide to the PSA blood test.
Doctors can refine a borderline PSA with two extra measurements. Free PSA describes the fraction of PSA that floats unbound in the blood; a lower percentage of free PSA points more toward cancer than toward benign enlargement. PSA density compares the PSA level to the size of the prostate measured on imaging, so a higher density raises concern. PSA is one of several tumor markers used in oncology, and you can see how it fits alongside the others in our explainer on tumour markers.
MRI before biopsy
A major shift in recent years is the use of multiparametric MRI before a biopsy. This detailed scan highlights suspicious areas and grades them on the PI-RADS scale from 1 (very unlikely to be significant cancer) to 5 (very likely). If the MRI is clear, many men can now safely avoid a biopsy altogether; if it shows a target, the biopsy can be aimed precisely at it.
The biopsy
A biopsy remains the only way to confirm prostate cancer. Using ultrasound or MRI guidance, a doctor takes a dozen or so tiny tissue cores, either through the rectum or through the skin behind the scrotum (the transperineal approach). A pathologist then examines the samples under a microscope.
Gleason score and Grade Groups
If cancer is found, the pathologist grades how abnormal the cells look. The traditional Gleason score adds the two most common cell patterns to give a number from 6 to 10. Because that scale confused many patients, doctors now also use Grade Groups from 1 to 5, where 1 is the least aggressive. Anything that is Grade Group 2 or higher is considered clinically significant — the kind of cancer worth treating or watching closely.
| Grade Group | Gleason score | What it typically means |
|---|---|---|
| Grade Group 1 | 6 (3+3) | Low grade; cells resemble normal tissue and usually grow slowly |
| Grade Group 2 | 7 (3+4) | Favorable intermediate; mostly well-formed glands |
| Grade Group 3 | 7 (4+3) | Unfavorable intermediate; more disorganized cells |
| Grade Group 4 | 8 | High grade; a clearly aggressive pattern |
| Grade Group 5 | 9 to 10 | Highest grade; most likely to grow and spread quickly |
Staging and PSMA PET
Staging asks whether the cancer has spread. For higher-risk cases, a newer scan called PSMA PET uses a tracer that attaches to a protein on prostate cells, lighting up disease anywhere in the body far more accurately than older bone scans and CT. The result can change the treatment plan by revealing spread that would otherwise be missed. Your PSA level, Grade Group, and stage are then combined into a risk category — low, intermediate, or high — that guides what happens next.
Treatment options for prostate cancer
Treatment depends on the cancer’s grade and stage, your age and overall health, and your own preferences. For many men the best first step is not immediate treatment at all.
Active surveillance
For low-risk disease (usually Grade Group 1), active surveillance means monitoring the cancer with periodic PSA tests, MRI, and occasional repeat biopsies, and treating only if signs of progression appear. It spares men the side effects of surgery or radiation for a tumor that may never need treatment. It differs from watchful waiting, which is less intensive monitoring aimed mainly at controlling symptoms later in life.
Surgery and radiation
Radical prostatectomy removes the entire prostate and is an option for cancer confined to the gland. Radiation therapy — delivered as external beams or as tiny radioactive seeds implanted in the prostate, a technique called brachytherapy — is an alternative with similar cure rates for localized disease. Both can cause urinary incontinence and erectile dysfunction; to understand the latter, read our article on the causes of erectile dysfunction.
Hormone therapy and advanced disease
Because most prostate cancers are fueled by male hormones (androgens) such as testosterone, lowering those hormones can slow the disease. Androgen deprivation therapy uses drugs such as leuprolide to switch off testosterone production, achieving what is sometimes called medical castration. When a cancer becomes resistant, newer pills push further: abiraterone shuts down testosterone production throughout the body by blocking a key enzyme, while enzalutamide blocks the androgen receptor — the docking point that testosterone uses to switch cancer cells on. Chemotherapy, such as docetaxel, is added for advanced, fast-growing disease.
Because hormone therapy lowers testosterone, some men develop symptoms of a hormone deficit. To understand that marker, see our overview of the testosterone blood marker, and for the wider condition, consult our guide to hypogonadism and low testosterone.
| Approach | Often suited for | Key considerations |
|---|---|---|
| Active surveillance | Low-risk (Grade Group 1) | Regular PSA, MRI, and repeat biopsy; treat only if the cancer progresses |
| Surgery (prostatectomy) | Localized disease, good life expectancy | Removes the gland; can affect urinary control and erections |
| Radiation therapy | Localized or locally advanced disease | External beams or seed implants; sometimes paired with hormone therapy |
| Hormone therapy (ADT) | Advanced or metastatic disease; alongside radiation | Lowers testosterone; side effects include hot flashes and fatigue |
| Chemotherapy | Advanced, castration-resistant disease | Often combined with hormone therapy |
Should you be screened? PSA testing and shared decisions
Screening means testing men who feel perfectly well in the hope of catching dangerous cancer early. With prostate cancer this is genuinely a judgment call, because screening can both save lives and lead to the discovery — and sometimes overtreatment — of harmless tumors.
The U.S. Preventive Services Task Force advises that men aged 55 to 69 make an individual decision about PSA screening after weighing the benefits and harms with a clinician; for men 70 and older it recommends against routine PSA screening. You can review the current USPSTF prostate cancer screening recommendation for the full wording.
Shared decision-making is the heart of it. A 55-year-old with a family history of aggressive disease may reasonably choose to test, while a 72-year-old with other serious health problems may reasonably decline. If you do test, remember that one high PSA reading is not a diagnosis — it is the start of a conversation.
When to talk to a doctor
- You are between 55 and 69 and want to weigh the pros and cons of PSA testing.
- You are Black or have a father or brother with prostate cancer; many guidelines suggest starting the conversation earlier, around age 40 to 45.
- You have urinary symptoms that are new, worsening, or bothersome.
- You notice blood in the urine or semen.
- You have persistent bone pain, especially in the back or hips.
Latest scientific advances in prostate cancer
Research over the past few years has reshaped how prostate cancer is detected and managed. Here is what the strongest recent studies mean for you, in plain language.
MRI first, biopsy second
A large Swedish screening trial known as GÖTEBORG-2, reported in 2024, found that performing an MRI first and skipping the biopsy when the scan is clear cut the diagnosis of harmless, clinically insignificant cancers by more than half — without meaningfully raising the risk of missing a dangerous one. What this means for you: fewer men endure an unnecessary biopsy, and fewer are burdened with a cancer label that never needed acting on.
More accurate staging with PSMA PET
An updated 2023 review of PSMA PET — the scan that makes prostate cells glow — concluded that it detects spread which older imaging misses and changes the management plan in roughly one in four men. What this means for you: treatment can be matched more closely to the true extent of the disease, avoiding both under-treatment and over-treatment.
Monitoring is a safe choice for low-risk disease
The British ProtecT trial followed men for a median of 15 years and found that those who chose active monitoring were no more likely to die of prostate cancer than those who had immediate surgery or radiation, although monitoring carried a somewhat higher chance of the cancer spreading. A large North American study called Canary PASS reported in 2024 that most men on protocol-based active surveillance avoid treatment for years and rarely develop metastasis (cancer that has spread to distant parts of the body). What this means for you: for low-risk cancer, careful monitoring is a legitimate, evidence-backed option, not doing nothing.
Screening helps, but selectively
The long-running European screening study (ERSPC), updated in 2025 after 23 years of follow-up, confirmed that PSA screening lowers the chance of dying from prostate cancer by about 13 percent, while a 15-year British trial (CAP) found a smaller benefit from a single PSA invitation. Both underline the same lesson: screening works best when it is risk-based and paired with MRI, so that dangerous cancers are found while harmless ones are left alone. What this means for you: the modern goal is smarter screening, not simply more screening.
Glossary
| Term | Definition |
|---|---|
| PSA (prostate-specific antigen) | A protein made by the prostate and measured in a blood test; higher levels can reflect cancer, benign enlargement, or infection. |
| Free PSA | The share of PSA circulating unbound in the blood; a lower percentage points more toward cancer. |
| PSA density | The PSA level divided by the prostate’s size on imaging; a higher value raises suspicion of significant cancer. |
| Gleason score | A grading system from 6 to 10 based on how abnormal cancer cells look under the microscope. |
| Grade Group | A simpler 1-to-5 scale derived from the Gleason score; Grade Group 2 or higher is considered clinically significant. |
| Multiparametric MRI | A detailed prostate scan that highlights suspicious areas and helps decide whether a biopsy is needed. |
| PI-RADS | A 1-to-5 score describing how likely an MRI finding is to be significant cancer. |
| PSMA PET | A scan using a tracer that binds a protein on prostate cells, used to find spread in higher-risk disease. |
| Active surveillance | Closely monitoring a low-risk cancer with PSA, MRI, and biopsies, treating only if it progresses. |
| Androgen deprivation therapy (ADT) | Treatment that lowers testosterone to slow hormone-driven prostate cancer. |
Frequently asked questions
What are the early warning signs of prostate cancer?
In its early stages, prostate cancer usually causes no symptoms at all, which is why testing decisions are important. When signs do appear, they often involve urination — a weak stream, trouble starting, or waking at night to go — but these are far more commonly caused by benign prostate enlargement. Blood in the urine or semen, or persistent back and hip pain, deserves prompt evaluation. No single symptom means cancer, but new or worsening changes are worth discussing with a doctor.
What PSA level is considered normal or concerning?
There is no universal cutoff. Many laboratories flag a PSA above 4 nanograms per milliliter for further discussion, but plenty of men with higher readings do not have cancer, and some with lower readings do. Age, prostate size, infection, and recent ejaculation all affect the number. That is why doctors look at trends over time and add tools such as free PSA, PSA density, and MRI rather than reacting to a single value.
Can prostate cancer be cured?
Yes. When prostate cancer is found while still confined to the gland, it is very often curable with surgery or radiation, and long-term survival is high. Many low-risk cancers do not even need immediate treatment and can be safely monitored. Even when the disease has spread, modern hormone therapies and other treatments can control it for years, although a cure becomes less likely at that stage.
What does my Gleason score or Grade Group mean?
The Gleason score (6 to 10) and Grade Group (1 to 5) both describe how aggressive the cancer cells look under the microscope. A Gleason 6, or Grade Group 1, is the least aggressive and is often suitable for active surveillance. Grade Group 2 or higher is considered clinically significant and usually prompts a discussion about treatment. Your score is one of several factors — along with PSA and stage — that shape your risk category and your options.
At what age should men consider prostate cancer screening?
For most men, the conversation begins around age 55 and continues to about 69, following the shared decision-making approach recommended by major guidelines. Men at higher risk — those of African descent or with a close relative who had prostate cancer — are often advised to start discussing screening earlier, around age 40 to 45. Routine PSA screening is generally not recommended after age 70. The right choice depends on your health, your values, and your risk.
Is active surveillance safe, or should the cancer be treated right away?
For low-risk prostate cancer, active surveillance is considered safe and is backed by long-term studies showing very low rates of death from the disease. It involves regular PSA tests, periodic MRI, and repeat biopsies so that treatment can begin promptly if the cancer shows signs of growing. It is not the same as ignoring the cancer. For intermediate-risk or high-risk disease, doctors usually recommend treatment rather than surveillance.
Sources
- Centers for Disease Control and Prevention (CDC) — Prostate Cancer Basics — cdc.gov
- National Cancer Institute — Prostate-Specific Antigen (PSA) Test — cancer.gov
- American Cancer Society — Tests to Diagnose and Stage Prostate Cancer — cancer.org
- U.S. Preventive Services Task Force — Prostate Cancer: Screening (2018) — uspreventiveservicestaskforce.org
- Hugosson J, et al. Results after Four Years of Screening for Prostate Cancer with PSA and MRI (GÖTEBORG-2) — New England Journal of Medicine, 2024 — doi.org/10.1056/NEJMoa2406050
- Hamdy FC, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT) — New England Journal of Medicine, 2023 — doi.org/10.1056/NEJMoa2214122
- Canary Prostate Active Surveillance Study (PASS) — Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer — JAMA, 2024 — doi.org/10.1001/jama.2024.6695
- Jochumsen MR, Bouchelouche K. PSMA PET/CT for Primary Staging of Prostate Cancer: An Updated Overview — Seminars in Nuclear Medicine, 2023 — doi.org/10.1053/j.semnuclmed.2023.07.001
- Roobol MJ, et al. European Study of Prostate Cancer Screening: 23-Year Follow-up (ERSPC) — New England Journal of Medicine, 2025 — doi.org/10.1056/NEJMoa2503223
- Martin RM, et al. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality (CAP) — JAMA, 2024 — doi.org/10.1001/jama.2024.4011
- Wei JT, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II — Journal of Urology, 2023 — doi.org/10.1097/JU.0000000000003492
- EMBL-EBI ChEMBL — Abiraterone, mechanism of action (CYP17A1 inhibitor) — ebi.ac.uk/chembl
- EMBL-EBI ChEMBL — Enzalutamide, mechanism of action (androgen receptor antagonist) — ebi.ac.uk/chembl
- EMBL-EBI ChEMBL — Leuprolide (GnRH agonist used for androgen deprivation therapy) — ebi.ac.uk/chembl
Further reading
- Follow our simple guide to reading blood test results.
- Read our urinalysis results interpretation guide.
- Check our guide to the kidney function panel.
- Consult our guide to the calcium and bone panel.
- Read our complete guide to the PSA blood test.
Understand your lab results with AI DiagMe
Get your results interpreted in minutes
A high PSA reading, a confusing Gleason score, or a follow-up panel checking your kidneys and calcium can be hard to interpret on your own. AI DiagMe helps you make sense of tests such as the PSA blood test, free PSA, and a kidney function panel by turning the numbers into clear, plain-language explanations reviewed by doctors. It is built to help you understand your results and prepare sharper questions for your physician — it does not diagnose prostate cancer and does not replace your doctor.
